Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Fampridine- b.i.d · 1 trial · 1 indication
All adverse events reported were treatment emergent. Therefore, events that had a date of onset, or worsening, on or after the start of the open-label drug and up to 14 days after the last dose (for non-serious events) or up to 30 days after the last dose (for SAEs) were summarized. Any abnormal clinically significant changes in physical examination, medical history, clinical laboratory testing, 12-lead ECG, and standard EEG testing were captured as adverse events.
| Name | Type | Description |
|---|---|---|
| Fampridine-SR b.i.d. (Twice Daily) | DRUG | Dosage form - tablets. |
Inclusion Criteria: * The subject must have been previously enrolled in an Acorda Therapeutics or an Elan Corporation sponsored study for multiple sclerosis and received either Fampridine or placebo. * The subject must have multiple sclerosis as determined by the Principal Investigator. * The subje...
Fampridine-b.i.d is an investigational small molecule being studied for the treatment of Multiple Sclerosis. It is in Phase 3 clinical development. The drug is being developed by cbdMD, Inc., which trades under the ticker YCBD.
Fampridine-b.i.d is a small molecule being studied in Multiple Sclerosis. Its specific molecular target has not been disclosed. The drug is in Phase 3 clinical development for this indication.
Fampridine-b.i.d is being developed by cbdMD, Inc., a company listed on the stock exchange under the ticker YCBD. The drug is currently in Phase 3 clinical trials for the treatment of Multiple Sclerosis.
Fampridine-b.i.d is in Phase 3 clinical development. It is an investigational drug being studied for Multiple Sclerosis and has not yet been approved by regulatory authorities. The drug is being developed by cbdMD, Inc.
Fampridine-b.i.d has one completed Phase 3 clinical trial, identified as NCT00654927. This open-label extension study evaluated the safety, tolerability, and activity of oral Fampridine-SR in patients with Multiple Sclerosis. The trial enrolled 177 participants in the United States and Canada.
Fampridine-b.i.d is also known as Fampridine-SR. The completed Phase 3 clinical trial NCT00654927 evaluated oral Fampridine-SR in patients with Multiple Sclerosis. The drug is being developed by cbdMD, Inc. for this indication.